Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Country:  U.S.A.
Trial Type:  Supportive care
Treatment/Intervention:  nausea and vomiting therapy
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Oral Versus Transdermal Ondansetron for Women With Cervical Cancer Receiving Chemoradiation
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-1107, NCI-2012-00221, NCT01536392
Efficacy of Aprepitant (Emend®) in Children
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 and under
Sponsor: Other
Protocol IDs: 0413, NCT01661335
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221301, NCI-2014-00446, U10CA031946, NCT02116530
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00031206, NCT01450826
Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: Merck-MISP-50440, NCT01874119
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 7 to 21
Sponsor: Other
Protocol IDs: 08-01-017, NCT00754286
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1B-11-5, NCI-2012-01170, NCT01649258
Start Over